Candriam Luxembourg S.C.A. decreased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 92,071 shares of the medical equipment provider’s stock after selling 6,274 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Zimmer Biomet Holdings were worth $10,781,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ZBH. Bronfman E.L. Rothschild L.P. increased its holdings in shares of Zimmer Biomet Holdings by 25.3% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after buying an additional 167 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Zimmer Biomet Holdings by 3.9% in the 2nd quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after buying an additional 33 shares during the last quarter. IHT Wealth Management LLC increased its holdings in shares of Zimmer Biomet Holdings by 28.4% in the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 256 shares during the last quarter. BB&T Investment Services Inc. purchased a new stake in shares of Zimmer Biomet Holdings in the 2nd quarter valued at $144,000. Finally, Sandy Spring Bank boosted its stake in shares of Zimmer Biomet Holdings by 5.4% in the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 66 shares in the last quarter. 85.80% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Shares Sold by Candriam Luxembourg S.C.A.” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/12/zimmer-biomet-holdings-inc-zbh-shares-sold-by-candriam-luxembourg-s-c-a.html.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down $1.09 during midday trading on Friday, hitting $110.75. 973,400 shares of the stock were exchanged, compared to its average volume of 1,738,246. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. The stock has a market cap of $22,423.88, a P/E ratio of 13.72, a PEG ratio of 1.72 and a beta of 1.17. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The business’s revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.79 EPS. equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current fiscal year.

ZBH has been the subject of a number of research reports. Gabelli initiated coverage on shares of Zimmer Biomet Holdings in a research note on Thursday, August 24th. They issued a “buy” rating and a $142.00 price objective for the company. Oppenheimer Holdings, Inc. set a $137.00 price objective on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Monday, August 14th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. SunTrust Banks, Inc. reissued a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet Holdings in a research report on Monday, October 2nd. Finally, Jefferies Group LLC reissued a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, November 3rd. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Zimmer Biomet Holdings has a consensus rating of “Hold” and a consensus target price of $134.00.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.